In Brief: NeoPath
This article was originally published in The Gray Sheet
NeoPath: Corning Clinical Laboratories will use the company's AutoPap 300 QC automated cervical cytology reader to conduct quality control for Pap smear screening. Corning, which operates 25 labs serving 44 states in the U.S., expects to install the first AutoPap system in its Wood Dale, Illinois facility in January. The agreement is the second for NeoPath since obtaining FDA approval for AutoPap on Sept. 29 ("The Gray Sheet" Oct. 9, p. 6). Earlier in October, the company signed a deal under which SmithKline Beecham Clinical Laboratories will install the automated system in its labs beginning in January...
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.